Opinion|Videos|August 19, 2024
Positioning PDS Within the Therapeutic Landscape
Author(s)Dennis M. Marcus, MD
Dr. Dennis Marcus discusses how the PDS with ranibizumab fits into the treatment landscape and explores other sustained delivery mechanisms currently in development for neovascular AMD.
Advertisement
Video content above is prompted by the following:
- How does the PDS with ranibizumab fit into the treatment landscape that also includes highly durable agents such as faricimab and high-dose aflibercept?
- What other sustained delivery mechanisms are currently in development for neovascular AMD?
Advertisement
Related to this article
Jicheng Lv, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to discuss 2-year TELIGAN data for telitacicept in IgAN.
A PROTECT biomarker analysis shows sparsentan reduced urinary sCD163, BAFF, C5b-9, and IL-6 vs irbesartan through 110 weeks in IgA nephropathy.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, review early MiniMed Vivera data on optional meal announcements and twiist's new type 2 diabetes clearance.
Real-world data in 1477 patients on dialysis show tenapanor reduced serum phosphate at 6 months with or without background phosphate binders.
Approval rests on the phase 3 AFFIRM trial, in which 56% of patients reached clinical remission at week 12 vs 30% with placebo.
Jean Elwing, MD, discusses what drove ralinepag's reduction in PAH clinical worsening in ADVANCE Outcomes and where the it could fit if approved.
Jean Elwing, MD, discusses a CHEST 2026 subgroup analysis showing ralinepag reduces clinical worsening in PAH even among patients with low-risk criteria.
Participants described earlier phenotyping, closer tracking of steroid exposure, and recognizing gradual gains on biologic therapy.
Advertisement
Advertisement
Trending on HCPLive
1
Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD
2
RAINIER: Povetacicept Cuts Proteinuria, Gd-IgA1 in IgA Nephropathy
3
Retatrutide Lowers Albuminuria, Glomerular Pressure in Obesity and CKD
4
FDA Approves Subcutaneous Risankizumab Induction for Crohn’s Disease
5